GEN Exclusives

More »

GEN News Highlights

More »
Jan 8, 2007

Xytis Receives $40M to Combat Cocaine Addiction

  • Xytis signed a $40-million CRADA with the NIDA to test the hypothesis that Neboglamine can facilitate abstinence from cocaine or prevent relapse in cocaine addiction. Neboglamine has been shown to improve cognitive performance and have anxiolytic and antidepressive activity in preclinical animal models, according to the company.

    The CRADA is subject to the completion of on-going multiple-dose escalating safety and tolerability studies. Xytis expects to complete this study during the second quarter of 2007. It is also subject to, the NIDA’s evaluation of the interaction of cocaine and Neboglamine in animals and humans.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Stopping Research Fraud

What is the best approach to curbing scientific misconduct and outright fraud?